Pathophysiological roles of interleukin-18 in inflammatory liver diseases

Immunological Reviews

Volumn 174, Issue , 2000, Pages 192-209

  Tsutsui, Hiroko ^a   Matsui, Kiyoshi ^a   Okamura, Haruki ^a   Nakanishi, Kenji ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BINDING PROTEIN; FAS LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 4; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HEPATITIS; IMMUNE RESPONSE; KUPFFER CELL; LIVER CELL; LIVER INJURY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION; VIRUS HEPATITIS;

EID: 0034083632     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0528.2002.017418.x     Document Type: Review

References (247)

1. 1. Kaneda K, Wake K. Distribution and morphological characteristics of the pit cells in the liver of the rat. Cell Tissue Res 1983;233:485-498.
2. 2. Rocha B, Guy-Grand D, Vassalli P. Extrathymic T cell differentiation. Curr Opin Immunol 1995;7:232-242.
3. 3. Abo T, et al. Extrathymic pathways of T-cell differentiation in the liver and other organs. Int Rev Immunol 1994;11:61-102.
4. 4. Naíto M, Hasegawa G, Takahashí K. Development, differentiation, and maturation of Kupffer cells. Microsc Res Tech 1997;15:350-364.
5. 5. Decker T, Kiderlen AF, Lohmann MML. Liver macrophages (Kupffer cells) as cytotoxic effector cells in extracellular and intracellular cytotoxicity. Infect Immun 1985;50:358-364.
6. + T cells but induces type I T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. J Immunol 1997;159:97-106.
7. 7. Hayashi N, et al. Kupffer cells from Schistosoma mansoni-infected mice participate in the prompt type 2 differentiation of hepatic T cells in response to worm antigen. J Immunol 1999;163:6702-6711.
8. 8. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-173.
9. 9. Pearce EJ, Caspar P, Grzych J-M, Lewis FA, She A. Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. J Exp Med 1991;173:159-166.
10. 10. Trinchieri G. Immunobiology of interleukin-12. Immunol Rev 1998;17:269-278.
11. 11. Okamura H, et al. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995;378:88-91.
12. 12. Tsutsui H, Mizoguchi Y, Morisawa S. Importance of direct hepatocytolysis by liver macrophages in experimental fulminant hepatitis. Hepatol Gastroenterol 1992;39:553-559.
13. 13. Kohno K, Kurimoto M. Molecule of the month: interleukin 18, a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both. Clin Immunol Immunopathol 1998;86:11-15.
14. 14. Fantuzzi G, Dinarello CA. Interleukin-18 and interleukin-1β: two cytokine substrates for ICE (caspase-1). J Clin Immunol 1999;19:1-11.
15. 15. Dinarello CA. Interleukin-1β, interleukin-18, and the interleukin-1β converting enzyme. Ann N Y Acad Sci 1998;856:1-11.
16. 16. Dinarello CA, et al. Overview of interleukin-18: more than an interferon-γ inducing factor. J Leukoc Biol 1998;63:658-664.
17. 17. Dinarello CA. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999;103:11-24.
18. 18. Dinarello CA. Interleukin-18. Methods 1999;19:123-132.
19. 19. Dinarello CA. Role of pro- and anti-inflammatory cytokines during inflammation: experimental and clinical findings. J Biol Regul Homeost Agents 1997;11:91-103.
20. 20. Okamura H, Kashiwamura S, Tsutsui H, Yoshimoto T, Nakanishi K. Regulation of interferon-γ production by IL-12 and IL-18. Curr Opin Immunol 1998;10:259-264.
21. 21. Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998;70:281-312.
22. 22. Okamura H Tsutsui H, Kashiwamura S-I, Yoshimoto T, Nakanishi K. Interleukin 18. In: Oppenheim JJ, Feldmann M, Durum SK, Hirano T, Vilcek J, Nicola NA, eds. Cytokine database. London: Academic Press (In press).
23. 23. Marshall JD, Aste AM, Chehimi SS, Murphy M, Olsen H, Trinchieri G. Regulation of human IL-18 mRNA expression. Clin Immunol 1999;90:15-21.
24. 24. Tsutsui H, et al. IL-18 accounts for both TNF-α-and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol 1997;159:3961-3967.
25. 25. Bazan JF, Timans JC, Kastelein RA. A newly defined interleukin-12 Nature 1996;379:591.
26. 26. Gu Y, et al. Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme. Science 1997;275:206-209.
27. 27. Ghayur T, et al. Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN-γ production. Nature 1997;386:619-623.
28. 28. Tone M, Thompson SA, Tone Y, Fairchild PJ, Waldmann H. Regulation of IL-18 (IFN-γ-inducing factor) gene expression. J Immunol 1997;159:6156-6163.
29. 29. Cosman D. Control of messenger RNA stability. Immunol Today 1987;8:16-17.
30. 30. Kim Y-M, et al. Roles of IFN consensus sequence binding protein and PU.1 in regulating IL-18 gene expression. J Immunl 1999;163:2000-2007.
31. 31. Driggers PH, et al. An interferon-γ-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I gene. Proc Natl Acad Sci USA 1990;87:3743-3747.
32. 32. Nelson Y, et al. Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation. J Immunol 1996;156:3711-3720.
33. 33. Politis AD, Ozato K, Coligan JE, Vogel SN. Regulation of IFN-γ-induced nuclear expression of IFN consensus sequence binding protein in murine peritoneal macrophages. J Immunol 1994;152:2270-2278.
34. 34. Sharf R, et al. Phosphorylation events modulate the ability of interferon consensus sequence binding protein to interact with interferon regulatory factors and to bind DNA. J Biol Chem 1997;272:9785-9792.
35. 35. Sharf R, Azriel A, Lejbkowicz F, Winograd SS, Ehrlich R, Levi B-Z. Functional domain analysis of interferon consensus sequence binding protein (ICSBP) and its association with interferon regulatory factors. J Biol Chem 1995;270:13063-13069.
36. +T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547-549.
37. 37. Gíese NA, et al. Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression. J Exp Med 1997;186:1535-1546.
38. 38. Scharton-Kersten T, Contursi C, Masumi A, Sher A, Ozato K. Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction. J Exp Med 1997;186:1523-1534.
39. 39. Wu C-Y, Maeda H, Contursi C, Ozato K, Seder RA. Differential requirement of IFN consensus sequence binding protein for the production of IL-12 and induction of Th1-type cells in response to IFN-γ. J Immunol 1999;162:807-812.
40. 40. Rosmarin AG, Caprio DG, Kirsh DG, Handa H, Simkevich CP. GABP and PU.1 compete for binding, yet cooperate to increase CD18 (β2 leukocyte integrin) transcription. J Biol Chem 1995;270:23627-23633.
41. 41. Moulton KS, Semple K, Wu H, Glass CK. Cell-specific expression of the macrophage scavenger receptor gene is dependent on PU.1 and a composite AP-1/ets motif. Mol Cell Biol 1994;14:4408-4418.
42. 42. Borras FE, Loberas J, Maki RA, Celada A. Repression of I-Ab gene expression by the transcription factor PU.1. J Biol Chem 1995;270:24385-24391.
43. 43. Pahl HL, et al. The proto-oncogene PU.1 regulates expression of the myeloid-specific CD11b promoter. J Biol Chem 1993;268:5014-5020.
44. 44. Shackelford R, Adams DO, Johnson SP. IFN-γ and lipopolysaccharide induce DNA binding of transcription factor PU.1 in murine tissue macrophages. J Immunol 1995;154:1374-1382.
45. 45. Sareneva T, Matikainen S, Kurimoto M, Julkunen I. Influenza A virus-induced IFN-α/β and IL-18 synergistically enhance IFN-γ gene expression in human T cells. J Immunol 1998;160:6032-6038.
46. 46. Torigoe K, et al. Purification characterization of the human interleukin-18 receptor. J Biol Chem 1997;272:25737-25742.
47. 47. Born TL, Thomassen E, Bird TA, Sims JE. Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J Biol Chem 1998;273:29445-29450.
48. 48. Cerretti DP, et al. Molecular cloning of the interleukin-1β converting enzyme. Science 1992;256:97-100.
49. 49. Thornbery NA, et al. A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 1992;356:768-774.
50. 50. Pirhonen J, Sareneve T, Kurimoto M, Julkunen I, Matikainen S. Virus infection activates IL-1β and IL-18 production in human macrophages by a caspase-1-dependent pathway. J Immunol 1999;162:7322-7329.
51. 51. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326:1-16.
52. 52. Alnemri ES, et al. Human ICE/CED-3 protease nomenclature. Cell 1996;87:171.
53. 53. Singer II, et al. The interleukin-1β-converting enzyme (ICE) is localized on the eternal cell surface membranes and in the cytoplasmic ground substance of human monocytes by immuno-electron microscopy. J Exp Med 1995;182:1447-1459.
54. 54. Wang S, Miura M, Jung Y-K, Zhu H, Li E, Yuan J. Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE. Cell 1998;92:501-509.
55. 55. Ramage P, et al. Expression, refolding, and autocatalytic proteolytic processing of the interleukin-1β-converting enzyme precursor. J Biol Chem 1995;270:9378-9383.
56. 56. Schumann RR, et al. Lipopolysaccharide activates caspase-1 (interleukin-1-converting enzyme) in cultured monocytic and endothelial cells. Blood 1998;91:577-584.
57. 57. Dimmeler S, Haendeler J, Nehls M, Zeiher AM. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1β-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J Exp Med 1997;185:601-607.
58. 58. Li J, Billiar TR, Talanian RV, Kim YM. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochem Biophys Res Commun 1997;240:419-424.
59. 59. Kim YM, Talanian RV, Li J, Billiar TR. Nitric oxide prevents IL-1β and IFN-γ-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1β-converting enzyme). J Immunol 1998;161:4122-4128.
60. 60. Lauw FN, et al. Interleukin-12 induces sustained activation of multiple host inflammatory mediator systems in chimpanzees. J Infect Dis 1999;179:646-652.
61. 61. Akita K, et al. Involvement of caspase-1 and caspase-3 in the production and processing of mature human interleukin 18 in monocytic THP.1 cells. J Biol Chem 1997;272:26595-26603.
62. 62. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T. Caspase-1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998;4:1287-1292.
63. 63. Tsutsui H, et al. Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 1999;11:359-367.
64. 64. Zhang J, Cado D, Chen A, Kabra NH, Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 1998;392:296-300.
65. 65. Yeh W-C, et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 1998;279:1954-1958.
66. 66. Muzio M, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-827.
67. 67. Enari M, Talanian RV, Wong WW, Nagata S. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 1996;380:723-726.
68. 68. Hirata H, et al. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med 1998;187:587-600.
69. 69. Imai Y, Kimura T, Murakami A, Yajima N, Sakamaki K, Yonehara S. The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis. Nature 1999;398:777-785.
70. 70. Krammer PH. CD95 (APO-1/Fas)-mediated apoptosis: live and let die. Adv Immunol 1999;71:163-210.
71. 71. Campanelli D, et al. Cloning of cDNA for proteinase 3: a serine protease, antibiotic, and autoantigen from human neutrophils. J Exp Med 1990;172:1709-1715.
72. 72. Mayet W-J, Csernok E, Szymkowiak C, Gross WL, Meyer zum Büschenfelde KH. Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis. Blood 1993;82:1221-1229.
73. 73. Csernok E, Lüdemann J, Gross WL, Bainton DF. Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis. Am J Pathol 1990;137:1113-1120.
74. 74. Ernst CM, Schmitt W, Bainton DF, Gross WL. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994;95:244-250.
75. 75. Hazuda DJ, Strickler J, Kueppers F, Simon PL, Young PR. Processing of precursor interleukin 1β and inflammatory disease. J Biol Chem 1990;265:6318-6322.
76. 76. Mizutani H, Schlechter N, Lazarus G, Black RA, Kupper TS. Rapid and specific conversion of precursor interleukin 1b (IL-1β) to an active IL-1 species by human mast cell chymase. J Exp Med 1991;174:821-825.
77. 77. Kapur V, Majesky MW, Li LL, Black RA, Musser JM. Cleavage of interleukin 1β (IL-1β) precursor to produce active IL-1β by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc Natl Acad Sci USA 1993;90:7676-7680.
78. 78. Schuönbeck U, Mach F, Libby P. Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing. J Immunol 1998;161:3340-3346.
79. 79. Robache-Gallea S, et al. In vitro processing of human tumor necrosis factor-α. J Biol Chem 1995;270:23688-23692.
80. 80. Moss ML, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997;385:733-736.
81. 81. Black RA, et al. A metalloproteinase disintegrin that releases tumor-necrosis factor-α from cells. Nature 1997;385:729-733.
82. 82. Longley BJ, et al. Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc Natl Acad Sci USA 1997;94:9017-9021.
83. 83. Irmler M, et al. Granzyme A is an interleukin 1β-converting enzyme. J Exp Med 1995;181:1917-1922.
84. 84. Fantuzzi G, Puren AJ, Harding MW, Livingston DJ, Dinarello CA. Interleukin-18 regulation of interferon γ production and cell proliferation as shown in interleukin-1β-converting enzyme (caspase-1)-deficient mice. Blood 1998;91:2118-2215.
85. 85. Bohn E, et al. IL-18 (IFN-γ-inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice. J Immunol 1998;160:299-307.
86. 86. Shibata Y, et al. Immunoregulatory roles of IL-10 in innate immunity: IL-10 inhibits macrophage production of IFN-γ-inducing factors but enhances NK cell production of IFN-γ. J Immunol 1998;161:4283-4288.
87. 87. Sanchez-Bueno A, Verkhusha V, Tanaka Y, Takikawa O, Yoshida R. Interferon-γ-dependent expression of inducible nitric oxide synthase, interleukin-12, and interferon-γ-inducing factor in macrophages elicited by allografted tumor cells. Biochem Biophys Res Commun 1996;224:555-563.
88. 88. Puren AJ, Fantuzzi G, Dinarello CA. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1β are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc Natl Acad Sci USA 1999;96:2256-2261.
89. 89. Stoll S, et al. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol 1998;28:3231-3239.
90. 90. De Saint-Vis B, et al. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol 1998;160:1666-1676.
91. 91. Stoll S, et al. Production of IL-18 (IFN-γ-inducing factor) messenger RNA and functional protein by murine keratinocytes. J Immunol 1997;159:298-302.
92. 92. Aragane Y, et al. IL-12 is expressed and released by human keratinocytes and epidermoid carcinoma cell lines. J Immunol 1994;153:5366-5372.
93. 93. Udagawa N, et al. Interleukin-18 (interferon-γ-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation. J Exp Med 1997;185:1005-1012.
94. 94. Olee T, Hashimoto S, Quach J, Lotz M. IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J Immunol 1999;162:1096-1100.
95. 95. Takeuchi M, et al. Intracellular production of interleukin-18 in human epithelial-like cell lines is enhanced by hyperosmotic stress in vitro. Cell Tissue Res 1999;297:467-473.
96. 96. Cameron LA, et al. Airway epithelium expresses interleukin-18. Eur Respir J 1999;14:553-559.
97. 97. Conti B, et al. Cultures of astrocytes and microglia express interleukin 18. Brain Res Mol Brain Res 1999;67:46-52.
98. 98. Prinz M, Hanisch UK. Murine microglial cells produce and respond to interleukin-18. J Neurochem 1999;72:2215-2218.
99. 99. Conti B, Jahng JW, Tinti C, Son JH, Joh TH. Induction of interferon-γ inducing factor in the adrenal cortex. J Biol Chem 1997;272:2035-2037.
100. 100. Hoshino K, et al. Generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol 1999;162:5041-5044.
101. 101. Yoshimoto T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J Immunol 1998;161:3400-3407.
102. 102. Tominaga K, et al. IL-12 synergizes with IL-18 or IL-1β for IFN-γ production from human T cells. Int Immunol 2000;12:151-160.
103. 103. Xu D, et al. Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. J Exp Med 1998;188:1485-1492.
104. 104. Kohno K, et al. IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol 1997;158:1541-1550.
105. 105. Hyodo Y, et al. IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. J Immunol 1999;162:1662-1668.
106. 106. Kunikata T, et al. Constitutive and induced IL-18 receptor expression by various peripheral blood cell subsets as determined by anti-hIL-18R monoclonal antibody. Cell Immunol 1998;189:135-143.
107. 107. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999;10:127-136.
108. 108. Aizawa Y, et al. Cloning and expression of interleukin-18 binding protein. FEBS Lett 1999;445:338-342.
109. 109. Xiang Y, Moss B. IL-18 binding and inhibition of interferon γ induction by human poxvirus-encoded proteins. Proc Natl Acad Sci USA 1999;96:11537-11542.
110. 110. Ray CA, et al. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme. Cell 1992;69:597-604.
111. 111. Robinson D, et al. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-γ production and activates IRAK and NF-κB. Immunity 1997;7:571-581.
112. 112. Matsumoto S, et al. Interleukin-18 activates NF-κB in murine T helper type 1 cells. Biochem Biophys Res Commun 1997;234:454-457.
113. 113. Kojima H, et al. Interleukin-18 activates the IRAK-TRAF6 pathway in mouse EL-4 cells. Biochem Biophys Res Commun 1998;244:183-186.
114. 114. Adachi O, et al. Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity 1998;9:143-150.
115. 115. Kanakaraj P, et al. Defective interleukin (IL)-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice. J Exp Med 1999;189:1129-1138.
116. 116. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-defident mice to endotoxin. Immunity 1999;11:115-122.
117. 117. Thomas JA, et al. Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase. J Immunol 1999;163:978-984.
118. 118. Hashimoto C, Hudson KL, Anderson KV. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmemebrane protein. Cell 1988;52:269-279.
119. 119. Lemaitre B, Reichhart JM, Hoffmann JA. Drosophila host defense: differential induction of antimicrobial peptide genes after infection by various classes of microorganisms. Proc Natl Acad Sci USA 1997;94:14614-14619.
120. 120. Gay NJ, Keith FJ. Drosophila Toll and IL-1 receptor. Nature 1991;315:355-356.
121. 121. O'Neill LA, Greene C. Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants. J Leukoc Biol 1998;63:650-657.
122. 122. Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A. The human Toll signaling pathway: divergence of nuclear factor κB and JNK/SAPK activation upstream of tumor necrosis factor-associated factor 6 (TRAF6). J Exp Med 1998;187:2097-2101.
123. 123. Medzhitov R, Preston-Hurburt P, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1998;91:295-298.
124. 124. Poltarak A, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice. Science 1998;282:2085-2088.
125. d/Ran of endotoxin-resistant C3H/HeJ mice is defective in mediating lipopolysaccharide endotoxin responses. Proc Natl Acad Sci USA 1999;96:11543-11548.
126. 126. Hoshino K, et al. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999;162:3749-3752.
127. 127. Takeuchi O, et al. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 1999;11:443-451.
128. 128. Yang R-B, et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signaling. Nature 1998;395:284-288.
129. 129. Kirschning CJ, Wesche H, Ayres TM, Rothe M. Human Toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J Exp Med 1998;188:2091-2097.
130. 130. Aliprantis AO, et al. Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2. Science 1999;285:736-739.
131. 131. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. Recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999;163:1-5.
132. 132. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 1999;274:17406-17409.
133. + T lymphocytes. J Immunol 1998;160:3642-3647.
134. + T cells: evidence for two distinct pathways for promoter activation. Eur J Immunol 1999;29:548-555.
135. 135. Xu X, Sun Y-L, Hoey T. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain. Science 1996;273:794-797.
136. 136. Jakobson NG, et al. Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activation of transcription (STAT) 3 and STAT 4. J Exp Med 1995;181:1755-1762.
137. 137. Thomassen E, Bird TA, Renshaw BR, Kennedy MK, Sims JE. Binding of interleukin-18 to the interleukin-1 receptor homologous receptor IL-1Rrp1 leads to activation of signaling pathways similar to those used by interleukin-1. J Interferon Cytokine Res 1998;18:1077-1088.
138. 138. Sica A, et al. Interaction of NF-κB and NFAT with the interferon-γ promoter. J Biol Chem 1997;272:30412-30420.
139. 139. Kojima H, et al. An essential role for NF-κB in IL-18-induced IFN-γ expression in KG-1 cells. J Immunol 1999;162:5063-5069.
140. 140. Ahn HJ, et al. A mechanism underlying synergy between IL-12 and IFN-γ-inducing factor in enhanced production of IFN-γ. J Immunol 1997;159:2125-2131.
141. 141. Hunter CA, et al. Comparison of the effects of interleukin-1α, interleukin-1β and interferon-γ-inducing factor on the production of interferon-γ by natural killer. Eur J Immunol 1997;27:2787-2792.
142. 142. Fehniger TA, et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 1999;162:4511-4520.
143. 143. Walker W, Aste AM, Kastelein RA, Trinchieri G, Hunter CA. IL-18 and CD28 use distinct molecular mechanisms to enhance NK cell production of IL-12-induced IFN-γ. J Immunol 1999;162:5894-5901.
144. - T cell subsets to express IL-18 receptor and produce IFN-γ in response to IL-18. J Immunol 1998;160:3759-3765.
145. 145. Munder M, Mallo M, Eichmann K, Modolell M. Murine macrophages secrete interferon γ upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med 1998;187:2103-2108.
146. 146. Lauwerys BR, Renauld JC, Houssiau FA. Inhibition of in vitro immunoglobulin production by IL-12 in murine chronic graft-vs.-host disease: synergism with IL-18. Eur J Immunol 1999;28:2017-2024.
147. 147. Takeda K, et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998;8:383-390.
148. 148. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-γ gene. Science 1993;259:1739-1742.
149. 149. Huang S, et al. Immune response in mice that lack the interferon-γ receptor. Science 1993;259:1742-1745.
150. 150. MacMicking JD, et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995;81:641-650.
151. 151. Wei XQ, et al. Altered immune response in mice lacking inducible nitric oxide synthase. Nature 1995;375:408-411.
152. 152. Nakanishi K, Yoshimoto T, Kashiwamura S-I, Tsutsui H, Okamura H. Potentiality of interleukin-18 as a useful reagent for the treatment of infectious diseases. In: Holland SM, ed. Cytokine therapeutics in infectious diseases. Philadelphia: Lippincott Williams & Wilkins (In press).
153. 153. Murphy KM. T lymphocyte differentiation in the periphery. Curr Opin Immunol 1998;10:226-232.
154. + effector T cells is differentially regulated by IL-18 and IL-12. J Immunol 1999;162:3202-3211.
155. 155. Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H. Interferon-γ-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol 1996;173:230-523.
156. 156. Dao T, Mehal WZ, Crispe IN. IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. J Immunol 1998;161:2217-2222.
157. 157. Ushio S, et al. Cloning of the cDNA for human IFN-γ-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 1996;156:4274-4279.
158. 158. Tsutsui H, et al. Interferon-γ-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 1996;157:3967-3973.
159. + T cell-mediated cytotoxicity. J Immunol 1999;162:2639-2647.
160. 160. Kayagaki N, et al. Expression and function of TNF-related apoptosis-inducing ligand (TRAIL) on murine activated NK cells. J Immunol 1999;163:1906-1913.
161. 161. Kägi D, Ledermann B, Bürki K, Zinkernagel RM, Hengartner H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol 1996;14:207-232.
162. 162. Shresta S, Heusel JW, Macivor DM, Wesseilschmidt RL, Russell JH, Ley TJ. Granzyme B plays a critical role in cytotoxic lymphocyte-induced apoptosis. Immunol Rev 1995;146:211-221.
163. 163. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-1456.
164. 164. Wiley SR, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-682.
165. 165. Pan G, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-113.
166. 166. Schneider P, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 1997;7:831-836.
167. 167. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 1997;7:821-830.
168. 168. Walczak H, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386-5397.
169. 169. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain Immunity 1997;7:813-820.
170. 170. French LE, Tschopp J. The TRAIL to selective tumor death. Nat Med 1999;5:146-147.
171. 171. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998;10:559-563.
172. 172. Micallef MJ, et al. In vivo antitumor effects of murine interferon-γ-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 1997;43:361-367.
173. 173. Micallef MJ, Tanimoto T, Kohno K, Ikeda M, Kurimoto M. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res 1997;57:4557-4563.
174. 174. Micallef MJ, Tanimoto T, Kohno K, Ikeda M, Ikegami H, Kurimoto M. Augmentation of in vitro interleukin 10 production after in vivo administration of interleukin 18 is activated macrophage-dependent and is probably not involved in the antitumor effects of interleukin 18. Anticancer Res 1999;18:4267-4274.
175. 175. Osaki T, et al. IFN-γ-inducing factor/IL-18 administration mediates IFN-γ-and IL-12-independent antitumor effects. J Immunol 1998;160:1742-1749.
176. 176. Hashimoto W, et al. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 1999;163:583-589.
177. + T cells in IL-12-induced immune responses in vivo. J Immunol 1998;160:16-19.
178. 178. Cui J, et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 1998;278:1623-1626.
179. 179. Osaki T, et al. Potent antitumor effects mediated by local expression of the mature form of the interferon-γ inducing factor, interleukin-18 (IL-18). Gene Ther 1999;6:808-815.
180. 180. Yamanaka K, et al. Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model. Cancer Immunol Immunother 1999;48:297-302.
181. 181. Magram J, et al. IL-12-deficient mice are defective in IFN-γ production and type 1 cytokine responses. Immunity 1996;4:471-481.
182. 182. Westphal O. Bacterial endotoxins. Int Arch Allergy Appl Immunol 1975;49:1-43.
183. 183. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. J Am Med Assoc 1993;269:1829-1835.
184. 184. Morrison DC, Ryan JL. Endotoxins and disease mechanisms. Annu Rev Med 1987;38:417-432.
185. 185. McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis 1999;19:205-219.
186. 186. Thurman RG. Mechanisms of hepatic toxicity II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 1998;275: G605-G611.
187. 187. Roth RA, Harkema JR, Pestka JP, Ganey PE. Is exposure to bacterial endotoxin a determinant of susceptibility to intoxication from xenobiotic agents? Toxicol Appl Pharmacol 1997;147:300-311.
188. 188. Nolan JP, Camara DS. Intestinal endotoxins as co-factors in liver injury. Immunol Invest 1989;18:325-337.
189. 189. Sakao Y, et al. IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock. Int Immunol 1999;11:471-480.
190. 190. Eberl G, Lees R, Smiley ST, Taniguchi M, Grusby MJ, MacDonald HR. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. J Immunol 1999;162:6410-6419.
191. + cells in the liver of mice. J Exp Med 1994;180:699-704.
192. pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 1994;179:1285-1295.
193. 193. Tsuji H, et al. Alleviation of lipopolysaccharide-induced acute liver injury in Propionibacterium acnes-primed IFN-γ-deficient mice by a concomitant reduction of TNF-α, IL-12, and IL-18 production. J Immunol 1999;162:1049-1055.
194. 194. Car BD, et al. Interferon γ receptor deficient mice are resistant to endotoxic shock. J Exp Med 1994;179:1437-1444.
195. 195. Rothe J, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993;364:798-802.
196. 196. Morikawa A, et al. Apoptotic cell death in the response of D-galactosamine-sensitized mice to lipopolysaccharide as an experimental endotoxic shock model. Infect Immun 1996;64:734-738.
197. 197. Nagata S. Apoptosis by death factor. Cell 1997;88:355-365.
198. 198. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995;16:39-43.
199. 199. Straus SE, Sneller M, Lenardo MJ, Puck JM, Strobere W. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Int Med 1999;130:591-601.
200. 200. Lenardo M, et al. Mature T lymphocyte apoptosis - immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 1999;17:221-253.
201. 201. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996;98:1107-1113.
202. 202. Bettinardi A, et al. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood 1997;89:902-909.
203. 203. Sneller MC, et al. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997;89:1341-1348.
204. 204. Kasahara Y, et al. Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder. Int Immunol 1998;10:195-202.
205. 205. Drappa J, Vaishnaw AK, Sullivan KE, Chu J-L, Elkon KB. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996;335:1643-1649.
206. 206. Rieux-Laucat F, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-1349.
207. 207. Fisher GH, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-946.
208. 208. Wang J, et al. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999;98:47-58.
209. 209. Ogasawara J, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-809.
210. 210. Tanaka M, et al. Fas ligand in human serum. Nat Med 1996;2:317-322.
211. 211. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997;3:409-413.
212. 212. Galle PR, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995;182:1223-1230.
213. 213. Strand S, et al. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat Med 1998;4:588-593.
214. 214. Taïeb J, Mathurin P, Poynard T, Gougerot-Pocidalo MA, Chollet-Martin S. Raised plasma soluble Fas and Fas ligand in alcoholic liver disease. Lancet 1998;351:1930-1931.
215. 215. Tanaka M, Suda T, Yatomi T, Nakamura N, Nagata S. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J Immunol 1997;158:2303-2309.
216. 216. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998;4:31-36.
217. 217. Oyaizu N, Kayagaki N, Yagita H, Pahwa S, Ikawa Y. Requirement of cell-cell contact in the induction of Jurkat T cell apoptosis: the membrane-anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat cells. Biochem Biophys Res Commun 1997;238:670-675.
218. 218. Rosenberg W. Mechanisms of immune escape in viral hepatitis. Gut 1999;44:759-764.
219. 219. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
220. 220. Alter MJ, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905.
221. 221. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-1108.
222. 222. Guidotti LG, Matzke B, Schaller H, Chisari FV. High-level hepatitis B virus replication in transgenic mice. J Virol 1995;69:6158-6169.
223. 223. Chisari FV, Ferrairi C. Hepaitits B virus immunopathology. Springer Semin Immunopathol 1995;17:261-281.
224. 224. Chisari FV. Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. Curr Top Microbiol Immunol 1996;206:149-173.
225. 225. Kawamura T, et al. Transgenic expression of hepatitis C virus structural proteins in the mouse. Hepatology 1997;25:1014-1021.
226. 226. Pasquinelli C, et al. Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology 1997;25:719-727.
227. 227. Wakita T, et al. Efficient conditional transgene expression in hepatitis C virus cDNA transgenic mice mediated by the Cre/loxP system. J Biol Chem 1998;273:9001-9006.
228. 228. Ando K, et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993;178:1541-1554.
229. 229. Nakamoto Y, Guidotti LG, Pasquetto V, Schreiber RD, Chisari FV. Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. J Immunol 1997;158:5692-5697.
230. 230. Kita H, et al. HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein. Hepatology 1993;18:1039-1044.
231. 231. Cerny A, McHutchison JG, Pasquinelli C, Brown ME, Brothers MA. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.2 binding motif. J Clin Invest 1995;95:521-530.
232. 232. Battegay M, et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 1995;69:2462-2470.
233. 233. Koziel MJ, et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992;149:3339-3344.
234. 234. Koziel MJ, et al. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol 1993;67:7522-7532.
235. 235. Koziel MJ, et al. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus: identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995;96:2311-2321.
236. + T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol 1999;162:6681-6689.
237. 237. Ando K, et al. Perforin, Fas/Fas ligand, and TNF-a pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 1997;158:5283-5291.
238. 238. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996;4:25-36.
239. 239. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-829.
240. 240. Penna A, et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 1997;25:1022-1027.
241. 241. Meyer zum Büschenfelde KH, Cramer S, Trumpfheller C, Fleischer B, Frosch S. Trypanosoma cruzi induces strong IL-12 and IL-18 gene expression in vivo: correlation with interferon-gamma (IFN-γ) production. Clin Exp Immunol 1997;110:378-385.
242. 242. Hoshino T, Wiltrout RH, Young HA. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J Immunol 1999;162:5070-5077.
243. 243. Zhang T, Kawakami K, Qureshi MH, Okamura H, Kurimoto M, Saito A. Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells. Infect Immun 1997;65:3594-3599.
244. 244. Garïa VE, et al. IL-18 promotes type 1 cytokine production from NK cells and T cells in human intracellular infection. J Immunol 1999;162:6114-6121.
245. 245. Yoshiraoto T, Okamura H, Tagawa YI, Iwakura Y, Nakanishi K. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-γ production from activated B cells. Proc Natl Acad Sci USA 1997;94:3948-3953.
246. 246. Yoshimoto T, et al. IL-18, although anti-allergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci USA 1999;96:13962-13966.
247. + human blood mononuclear cells. J Clin Invest 1998;101:711-721.